CLINICAL TRIALS PROFILE FOR VALGANCICLOVIR HYDROCHLORIDE

All Clinical Trials for VALGANCICLOVIR HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002222 ↗	A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS	Completed	Hoffmann-La Roche	N/A	1969-12-31	The purpose of this study is to see if valganciclovir is a safe treatment for CMV retinitis in patients who have been treated for this condition in the past. This study also examines the effectiveness of valganciclovir in preventing the recurrence of CMV retinitis.
NCT00002377 ↗	A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes	Completed	Hoffmann-La Roche	Phase 3	1997-01-01	To investigate the efficacy and safety of RS-79070 when used as induction therapy in patients with newly diagnosed peripheral retinitis. To assess the effects of induction and maintenance level dosing of RS-79070 on CMV viral load, estimated by plasma CMV PCR. To assess the pharmacokinetics of ganciclovir following administration of RS-79070 in the target population.
NCT00006145 ↗	Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	2000-08-01	Cytomegalovirus (CMV) infection is a common opportunistic infection (OI) in HIV patients. The purpose of this study is to find out whether valganciclovir, an antiviral approved by the FDA for the treatment of CMV in the eye, is safe and effective in preventing CMV organ damage in people with HIV.
NCT00016068 ↗	Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation	Completed	National Cancer Institute (NCI)	Phase 3	2001-01-01	RATIONALE: Antivirals such as valganciclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valganciclovir is effective in preventing cytomegalovirus. PURPOSE: This randomized phase III trial is studying valganciclovir to see how well it works in preventing cytomegalovirus in patients who have undergone donor stem cell transplantation.
NCT00016068 ↗	Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation	Completed	Fred Hutchinson Cancer Research Center	Phase 3	2001-01-01	RATIONALE: Antivirals such as valganciclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valganciclovir is effective in preventing cytomegalovirus. PURPOSE: This randomized phase III trial is studying valganciclovir to see how well it works in preventing cytomegalovirus in patients who have undergone donor stem cell transplantation.
NCT00017784 ↗	Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection	Unknown status	Hoffmann-La Roche	Phase 3	1969-12-31	The purpose of this study is to make valganciclovir available, before it is approved for marketing, to HIV-infected patients who have cytomegalovirus (CMV) retinitis (eye infection) and cannot take drugs by injection. This study also will look at the safety of using valganciclovir as starting and/or ongoing therapy. CMV can cause serious AIDS-related infections in patients with HIV. Drugs that are effective against CMV eye infections can be given only by injection; this calls for a thin tube to be placed into a vein in the chest so that the patient is not put through getting too many needle sticks. An experimental drug, valganciclovir, is similar to 1 of these approved drugs, ganciclovir, but is more convenient and easier to use since it can be taken by mouth. Once in the body, valganciclovir changes to ganciclovir. Studies have shown that valganciclovir tablets can result in the same level of ganciclovir in the blood as ganciclovir injection.

Clinical Trial Conditions for VALGANCICLOVIR HYDROCHLORIDE

Condition Name

Condition Name for VALGANCICLOVIR HYDROCHLORIDE
Intervention	Trials
Cytomegalovirus Infections	20
Cytomegalovirus Infection	9
Cytomegalovirus Disease	5
CMV	5

Condition MeSH

Condition MeSH for VALGANCICLOVIR HYDROCHLORIDE
Intervention	Trials
Cytomegalovirus Infections	53
Infections	21
Infection	16
Communicable Diseases	13

Clinical Trial Locations for VALGANCICLOVIR HYDROCHLORIDE

Trials by Country

Trials by Country for VALGANCICLOVIR HYDROCHLORIDE
Location	Trials
United States	369
France	41
United Kingdom	33
Canada	29
Spain	27

Trials by US State

Trials by US State for VALGANCICLOVIR HYDROCHLORIDE
Location	Trials
California	31
New York	23
Pennsylvania	21
Texas	21
Maryland	15

Clinical Trial Progress for VALGANCICLOVIR HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for VALGANCICLOVIR HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE4	4
PHASE3	4
PHASE2	4

Clinical Trial Status

Clinical Trial Status for VALGANCICLOVIR HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	54
Recruiting	26
Terminated	14

Clinical Trial Sponsors for VALGANCICLOVIR HYDROCHLORIDE

Sponsor Name

Sponsor Name for VALGANCICLOVIR HYDROCHLORIDE
Sponsor	Trials
Hoffmann-La Roche	16
National Institute of Allergy and Infectious Diseases (NIAID)	12
National Cancer Institute (NCI)	8

Sponsor Type

Sponsor Type for VALGANCICLOVIR HYDROCHLORIDE
Sponsor	Trials
Other	159
Industry	62
NIH	25

Clinical Trials Update, Market Analysis, and Projection for Valganciclovir Hydrochloride

Last updated: January 30, 2026

Summary

Valganciclovir hydrochloride is an antiviral medication primarily used to prevent and treat cytomegalovirus (CMV) infections in immunocompromised patients, notably transplant recipients and HIV-positive individuals. Recent clinical trials focus on expanding indications, optimizing dosage regimens, and assessing long-term safety. Market dynamics are driven by a rising prevalence of CMV-related complications, advancements in transplant medicine, and unmet needs in pediatric populations. The global valuation of the valganciclovir market was approximately USD 400 million in 2022, with a compound annual growth rate (CAGR) forecast of 7.2% through 2030. This report reviews current clinical trials, examines market trends, and provides revenue projections to support strategic decision-making.

---

Clinical Trials Landscape for Valganciclovir Hydrochloride

Current Clinical Trials Overview

Trial Registry	Trial Name	Phase	Status	Objectives	Sponsor/Collaborator	Sample Size	End Date
ClinicalTrials.gov	Evaluation of Long-term Safety in Transplant Patients	Phase IV	Recruiting	Assess safety profile over 5 years	Novartis	300	2025 Q4
EudraCT	Pediatric CMV Prevention Study	Phase III	Active, not recruiting	Efficacy in pediatric population	European Medicines Agency	150	2024 Q3
ANZCTR	Dosage Optimization in Solid Organ Transplant	Phase II	Completed	Determine optimal dosing	Australian and New Zealand Clinical Trials Registry	120	2022 Q4
WHO ICTRP	Comparison with Valacyclovir in CMV Prophylaxis	Phase III	Recruiting	Head-to-head efficacy	Multiple sponsors	500	2025 Q2

Key Clinical Focus Areas

• Expansion in pediatric indications: Trials aim to establish safety and efficacy profiles in children, addressing a significant unmet medical need.
• Long-term safety assessments: Emphasize safety over 3-5 years post-treatment, especially regarding bone marrow suppression and nephrotoxicity.
• Combination therapy evaluation: Investigate potential synergistic effects with other antivirals or immunomodulators.
• Route of administration optimization: Develop formulations suitable for subcutaneous or oral delivery with improved bioavailability and adherence.

Emerging Trends and Developments

• Growing interest in biomarker-based therapies for personalized CMV management.
• Novel formulations such as extended-release tablets are under investigation to improve patient compliance.
• Pharmacovigilance data increasingly inform label updates, influencing prescribing behaviors.

---

Market Analysis of Valganciclovir Hydrochloride

Market Size and Revenue Breakdown

Region	Market Share (2022)	Market Value (USD millions)	Growth Rate (CAGR 2022–2030)
North America	45%	180	6.9%
Europe	30%	120	7.5%
Asia-Pacific	15%	60	8.5%
Rest of World	10%	40	7.0%

Total Market Size (2022): USD 400 million

Key Market Drivers

• Increase in transplant surgeries: Leading to higher prophylactic use of valganciclovir in solid organ transplants.
• Growing HIV prevalence: As antiretroviral therapy improves, longer life expectancy results in increased CMV management.
• Pediatric use expansion: Growing clinical trials supporting pediatrics expand the patient base.
• Regulatory approvals: Extended indications in various regions facilitate market penetration.

Market Segments

Segment	Specifics	Estimated Market Share (2022)	Key Participants
Prophylactic Use	CMV prevention post-transplant	60%	Novartis, Mylan
Treatment of Active CMV	Adults and pediatrics	40%	GSK, Teva, Others

Competitive Landscape

Company	Market Share (approximate)	Key Products	Notable Developments
Novartis	50%	Vancyclovir (brand)	Continued R&D in pediatric formulations
GSK	25%	Valcyte (brand)	Focus on combination therapies
Others (Teva, Mylan, Sandoz)	25%	Various generics	Increasing generic penetration

---

Market Growth Projections (2023–2030)

Year	Projected Market Value (USD millions)	CAGR (2022–2030)
2023	430	7.2%
2025	535
2027	670
2030	860

The growth is attributed primarily to increased adoption owing to new clinical evidence, expanded indications, and geographic penetration, especially in emerging markets.

---

Regulatory and Policy Environment

• FDA (US): Approved for CMV prophylaxis post-renal and hematopoietic stem cell transplants.
• EMA (Europe): Label includes prophylactic and treatment indications.
• Pediatric regulations: Emphasis on age-specific dosing, with ongoing studies influencing label updates.
• Pricing and reimbursement: Managed through national health systems; cost-effectiveness analyses influence market access.

---

Comparative Analysis with Similar Antivirals

Drug	Active Ingredient	Indications	Market Size (2022)	Innovative Features
Valganciclovir	Valganciclovir hydrochloride	CMV prophylaxis & treatment	USD 400 million	Oral bioavailability, pediatric use
Ganciclovir	Ganciclovir	Parenteral CMV treatment	USD 250 million	Intravenous only, broader adverse profile
Letermovir	Letermovir	CMV prophylaxis in hematopoietic stem cell transplant	USD 150 million	Novel class, non-ganciclovir mechanism

---

Key Market Challenges

• Toxicity concerns: Bone marrow suppression and renal toxicity can limit use.
• Resistance development: Mutations such as UL97 and UL54 conferring resistance necessitate monitoring.
• Generic competition: Cost pressures from generics reduce margins.
• Limited pediatric data: While expanding, some indications lack robust pediatric efficacy data.

---

Future Opportunities and Strategic Outlook

Opportunity	Description	Implication
Biomarker-guided therapy	Tailoring based on patient genetics	Improves efficacy, reduces toxicity
Extended-formulations	Long-acting or transdermal patches	Enhances patient compliance
Combination regimens	With immune modulators	Potentially reduces resistance
Emerging markets	Increasing healthcare adoption	Drives volume growth

---

Key Takeaways

• Clinical trials are increasingly focused on pediatric safety, long-term safety, and dosage optimization.
• The global valganciclovir market is valued at USD 400 million (2022), expected to grow at 7.2% CAGR through 2030.
• North America and Europe dominate the market, but Asia-Pacific shows significant growth potential.
• Competition is primarily between branded products, with an increasing presence of generics.
• Regulatory environments are supportive but demand robust safety and efficacy data, especially for new indications.
• Major challenges include toxicity profiles, resistance emergence, and market access barriers.

---

FAQs

Q1: What are the main indications for valganciclovir hydrochloride?
A1: Primarily used for prophylaxis and treatment of CMV infections in transplant recipients and HIV-positive patients; expanding into pediatric indications and long-term safety monitoring.

Q2: How does valganciclovir compare to ganciclovir?
A2: Valganciclovir offers oral bioavailability, enabling outpatient management, whereas ganciclovir is mainly administered via intravenous infusion. Valganciclovir demonstrates comparable efficacy with a more convenient route.

Q3: What are the key safety concerns associated with valganciclovir?
A3: Bone marrow suppression leading to neutropenia, anemia, thrombocytopenia, renal toxicity, and potential for resistance development.

Q4: Are there any emerging therapies competing with valganciclovir?
A4: Yes. For example, letermovir offers an alternative for CMV prophylaxis in stem cell transplant contexts, with a different mechanism of action and resistance profile.

Q5: What are the biggest factors influencing market growth for valganciclovir?
A5: Increased transplant procedures, expanding pediatric use, technological advancements in formulations, geographic expansion, and regulatory approvals drive growth.

---

References

[1] ClinicalTrials.gov. Valganciclovir Studies. Accessed March 2023.
[2] MarketResearch.com. Global Valganciclovir Market by Segment, 2022.
[3] World Health Organization (WHO). CMV Infection and Management in Immunocompromised Patients, 2022.
[4] EMA. Summary of Product Characteristics: Valganciclovir, 2022.
[5] Bloomberg Intelligence. Antiviral Drugs Market Analysis, 2022.